Table 1.
Recent reports for generating human iPSC-derived macrophages
| Study | Cultural dimension | Culture period (days) |
Surface marker profiling | Direct comparison to primary cells (surface marker) |
Cytokine profiling | Direct comparison to primary cells (cytokine) |
Disease application |
|---|---|---|---|---|---|---|---|
| Wilgenburg et al., 2013 | 3D | 21 | CD14, CD16, CD163, CD86, MHCⅡ, CD206 | Yes | Yes (36 kinds) |
No | No |
| Yanagi-machi et al., 2013 | 2D | 23–35 | CD14, CD68, CX3CR1, CD86, CD80, CD163, CD206, HLA-DR | Yes | Yes (2 kinds) |
Yes | No |
| Lachmann et al., 2015 | 3D | 22–30 | CD14, CD45, CD11b, CD163, CD86, TRA-1–60, CD34, CD19, CD66b | Yes | Yes (12 kinds) |
Yes | No |
| Zhang et al., 2015 | 3D | 22 | CD43,CD34,CD18,CD45,CD11b/c,CD14,CD16,CD115,CX3CR1,CCR2,CD1a,CD83,CD3,CD19 | Yes | Yes (36 kinds) |
Yes | Yes (Mendelian disease) |
| Takata et al., 2017 | 2D | 26 | CD14, CD45, CD11b, CD163, CX3CR1 | No | Yes (16 kinds) |
Yes (only to disease model) |
Yes (familial Mediterranean fever) |
| Hong et al., 2018 | 3D | 35–40 | CD11b, CD14, CD40, CD68, MHCⅡ | No (only to THP-1 cell line) |
No | No | Yes (Tuberculosis infection) |
| Cao et al., 2019 | 2D | 19 | CD45, CD11b, CD18, CD163, CD80, CD206 | Yes | Yes (11 kinds) |
Yes | No |
| Nenasheva et al., 2020 | 3D | 22–27 | CD45, CD11b, CD64, CD16, CD80, CD86, HLA-DR, CD195, CD163, CD206 | Yes | Yes (41 kinds) |
Yes | No |
| This report | 2D/3D | 19/22 | CD45, CD34, CD11b, CD14, CD163, CD80, CD206 | Yes | Yes (65 kinds) |
Yes | Yes (FOP) |